The results indicate that the inhibition of pro-survival PI3K/AKT and MAPK/ERK signaling pathways may enhance the effect of niclosamide-induced cell death and thereby niclosamide may be a novel effective anticancer agent against grade IV glioblastoma like the U-87 MG cell line. Here, AKT1 is linked to glioblastoma.